ENTRY       D10444                      Drug
NAME        Lirilumab (USAN/INN)
FORMULA     C6452H9918N1698O2030S46
EXACT_MASS  145137.2203
MOL_WEIGHT  145226.9339
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGSSVKV SCKASGGTFS FYAISWVRQA PGQGLEWMGG FIPIFGAANY
            AQKFQGRVTI TADESTSTAY MELSSLRSDD TAVYYCARIP SGSYYYDYDM DVWGQGTTVT
            VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
            QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG
            PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
            STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
            MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
            QEGNVFSCSV MHEALHNHYT QKSLSLSLG
            (Light chain)
            EIVLTQSPVT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
            RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWMYTFGQ GTKLEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H137-L214, H150-H206, H229-H'229, H232-H'232, H264-H324, H370-H428, H'22-H'96, H'137-L'214, H'150-H'206, H'264-H'324, H'370-H'428, L23-L88, L134-L194, L'23-L'88, L'134-L'194; Modified residue: H1', H1' Q=pyroglutamic acid [CPD:C01879]; Glycosylation site: H300, H'300)
  TYPE      Peptide
EFFICACY    Antineoplastic, Anti-KIR antibody
  TYPE      Monoclonal antibody
COMMENT     Solid and hematological cancers
TARGET      KIR2DL (CD158) [HSA:3802 3803 3804] [KO:K07981]
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                KIR2DL (CD158)
                 D10444  Lirilumab (USAN/INN)
DBLINKS     CAS: 1000676-41-4
            PubChem: 172232537
///
